Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Mesothelin Promotes Acute Myeloid Leukemia Cell Proliferation, Adhesion, and Chemoresistance through Novel Binding Partner Lyn

Josh R Faust, Anilkumar Gopalakrishnapillai, Sonali P Barwe

Blood (2024) 144 (Supplement 1): 4103.

https://doi.org/10.1182/blood-2024-208794

Published: 2024

Journal Articles

Identification of DLK1 As a Novel Therapeutic Target in Down Syndrome Myeloid Leukemia

Sonali P Barwe, Meredith Tavenner, Patrick Van Berkel, Aimy Sebastian, Rhonda E. Ries, Soheil Meshinchi, Johann K. Hitzler, Yana Pikman, Anders Kolb, Anilkumar Gopalakrishnapillai

Blood (2024) 144 (Supplement 1): 209.

https://doi.org/10.1182/blood-2024-211364

Published: 2024

Journal Articles

Interferon Synergizes with Inhibition of Pro-Apoptotic Proteins to Reduce Leukemia Burden in PDX Models of ML-DS

Sonali P Barwe, Neha Bhagwat, Anilkumar Gopalakrishnapillai

Blood (2024) 144 (Supplement 1): 4156.

https://doi.org/10.1182/blood-2024-209899

Published: 2024

Journal Articles

A Bone Marrow Mimetic 3D Co-Culture Model for Ex Vivo drug Testing of Down Syndrome-Myeloid Leukemia Cells

Ishnoor Sidhu, Sonali P. Barwe, Kristi Lynn Kiick, E. Anders Kolb, Anilkumar Gopalakrishnapillai

Blood (2022) 140 (Supplement 1): 8805–8806.

https://doi.org/10.1182/blood-2022-170637

Published: 2022

Journal Articles

Azacitidine and Panobinostat Overcome Bone Marrow Microenvironment-Induced Chemoprotection in KMT2A- rearranged Pediatric AML

Kara Lehner, Anilkumar Gopalakrishnapillai, E. Anders Kolb, Sonali P. Barwe

Blood (2022) 140 (Supplement 1): 5963–5964.

https://doi.org/10.1182/blood-2022-171114

Published: 2022

Journal Articles

Preclinical Validation of EZH2 and HDAC I Dual Inhibition As a Potent Therapy for Refractory Myeloid Leukemia Associated with Down Syndrome

Kader Cicek, Joshua R. Faust, Meredith Tavenner, E. Anders Kolb, Sonali P. Barwe, Anilkumar Gopalakrishnapillai

Blood (2022) 140 (Supplement 1): 5951–5952.

https://doi.org/10.1182/blood-2022-170549

Published: 2022

Journal Articles

Selinexor Prolongs Survival in Patient-Derived Xenograft Models of Down Syndrome Myeloid Leukemia

Sonali P. Barwe, Yana Pikman, E. Anders Kolb, Anilkumar Gopalakrishnapillai

Blood (2022) 140 (Supplement 1): 8817–8818.

https://doi.org/10.1182/blood-2022-170441

Published: 2022

Journal Articles

The menin-MLL1 interaction is a molecular dependency in NUP98 -rearranged AML

Emily B. Heikamp, Jill A. Henrich, Florian Perner, Eric M. Wong, Charles Hatton, Yanhe Wen, Sonali P. Barwe, Anilkumar Gopalakrishnapillai, Haiming Xu, Hannah J. Uckelmann, Sumiko Takao, Yaniv Kazansky, Yana Pikman, Gerard M. McGeehan, Edward A. Kolb, Alex Kentsis, Scott A. Armstrong

Blood (2022) 139 (6): 894–906.

https://doi.org/10.1182/blood.2021012806

Published: 2022

Includes: Supplemental data

Journal Articles

T Cell Engaging Bispecific Antibodies Produce Durable Response in Mesothelin-Positive Patient-Derived Xenograft Models of Pediatric AML

Anilkumar Gopalakrishnapillai, Colin Correnti, Kristina Pilat, Ida Lin, Albe Man Kid Chan, Ashok D. Bandaranayake, Christopher Mehlin, Anne Kisielewski, Darcy Hamill, Allison Kaeding, Soheil Meshinchi, James Olson, E. Anders Kolb, Sonali P. Barwe

Blood (2021) 138 (Supplement 1): 1280.

https://doi.org/10.1182/blood-2021-151907

Published: 2021

Journal Articles

Hydrogel-Based 3D Culture Model for Down Syndrome Associated Transient Myeloproliferative Disorder Using Customized Induced Pluripotent Stem Cells

Ishnoor Sidhu, Sonali P. Barwe, Kristi Lynn Kiick, E. Anders Kolb, Anilkumar Gopalakrishnapillai

Blood (2021) 138 (Supplement 1): 1137.

https://doi.org/10.1182/blood-2021-151274

Published: 2021

Journal Articles

Introduction of STAG2 Mutation in an iPSC Model of Transient Abnormal Myelopoiesis Mimics Down Syndrome Myeloid Leukemia

Ishnoor Sidhu, Sonali P. Barwe, E. Anders Kolb, Anilkumar Gopalakrishnapillai

Blood (2021) 138 (Supplement 1): 1138.

https://doi.org/10.1182/blood-2021-151875

Published: 2021

Journal Articles

Evaluating the Efficacy of PRMT5 Inhibitor C220 in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia

Anilkumar Gopalakrishnapillai, Anne Kisielewski, Yang Zhang, Bruce Ruggeri, Peggy Scherle, E. Anders Kolb, Sonali P. Barwe

Blood (2021) 138 (Supplement 1): 1170.

https://doi.org/10.1182/blood-2021-151671

Published: 2021

Journal Articles

Bcl2 Inhibitor and DNA Hypomethylating Agent Prolong Survival in Patient-Derived Xenograft Model of Down Syndrome Myeloid Leukemia By Synergistic Downregulation of Cytokine Signaling

Sonali P. Barwe, Erin Lynn Crowgey, Qinzhuo Zhang, E. Anders Kolb, Anilkumar Gopalakrishnapillai

Blood (2021) 138 (Supplement 1): 3452.

https://doi.org/10.1182/blood-2021-154391

Published: 2021

Journal Articles

Epigenetic Drug Combination Alters Methylation Patterns in Patient-Derived Xenograft Models of KMT2A -Rearranged Pediatric AML Treated In Vivo

Anilkumar Gopalakrishnapillai, Erin Lynn Crowgey, Adam Marsh, E. Anders Kolb, Sonali P. Barwe

Blood (2021) 138 (Supplement 1): 2376.

https://doi.org/10.1182/blood-2021-154456

Published: 2021

Journal Articles

Imetelstat Significantly Reduces Leukemia Stem Cells in Patient-Derived Xenograft Models of Pediatric AML

Sonali P. Barwe, Fei Huang, E. Anders Kolb, Anilkumar Gopalakrishnapillai

Blood (2021) 138 (Supplement 1): 3352.

https://doi.org/10.1182/blood-2021-151607

Published: 2021

Journal Articles

Mesothelin Expression Is Associated with Extramedullary Disease and Promotes In Vivo Leukemic Growth in Acute Myeloid Leukemia

Katherine Tarlock, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Quy Le, PhD, Thao T. Tang, Darcy Hamill, DO, Anilkumar Gopalakrishnapillai, PhD, Sonali Barwe, PhD MSc, Rhonda E. Ries, MA, Richard Aplenc, MD PhD, Andrew C. Wood, MD, E. Anders Kolb, MD, Soheil Meshinchi, MDPhD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-134821

Published: 2020

Journal Articles

Mesothelin Targeting Bites for Pediatric AML: In Vivo Efficacy and Specificity

Anilkumar Gopalakrishnapillai, PhD, Colin Correnti, PhD, Anne Kisielewski, BS, Allison Kaeding, MD, Soheil Meshinchi, MD PhD, E. Anders Kolb, MD, Sonali Barwe, PhD MSc

Blood (2019) 134 (Supplement_1): 3925.

https://doi.org/10.1182/blood-2019-130941

Published: 2019

Journal Articles

A Hydrogel Based 3D Culture System for Hematopoietic Differentiation of Induced Pluripotent Stem Cells

Ishnoor Sidhu, Sonali Barwe, PhD MSc, E. Anders Kolb, MD, Kristi Lynn Kiick, PhD, Anilkumar Gopalakrishnapillai, PhD

Blood (2019) 134 (Supplement_1): 5010.

https://doi.org/10.1182/blood-2019-130949

Published: 2019

Journal Articles

Modeling Transient Myeloproliferative Disorder Using Induced Pluripotent Stem Cells and CRISPR/Cas9 Technology

Sonali Barwe, PhD MSc, E. Anders Kolb, MD, Anilkumar Gopalakrishnapillai, PhD

Blood (2019) 134 (Supplement_1): 2738.

https://doi.org/10.1182/blood-2019-130934

Published: 2019

Journal Articles

Generation, Characterization and Pre-Clinical Drug Evaluation of Patient-Derived Xenograft Models of Pediatric Down Syndrome AML

Sonali Barwe, PhD MSc, E. Anders Kolb, MD, Erin Lynn Crowgey, PhD, Todd E Druley, MD PhD, Anilkumar Gopalakrishnapillai, PhD

Blood (2019) 134 (Supplement_1): 2683.

https://doi.org/10.1182/blood-2019-131050

Published: 2019

NARROW

Mesothelin Promotes Acute Myeloid Leukemia Cell Proliferation, Adhesion, and Chemoresistance through Novel Binding Partner Lyn

Identification of DLK1 As a Novel Therapeutic Target in Down Syndrome Myeloid Leukemia

Interferon Synergizes with Inhibition of Pro-Apoptotic Proteins to Reduce Leukemia Burden in PDX Models of ML-DS

A Bone Marrow Mimetic 3D Co-Culture Model for Ex Vivo drug Testing of Down Syndrome-Myeloid Leukemia Cells

Azacitidine and Panobinostat Overcome Bone Marrow Microenvironment-Induced Chemoprotection in KMT2A- rearranged Pediatric AML

Preclinical Validation of EZH2 and HDAC I Dual Inhibition As a Potent Therapy for Refractory Myeloid Leukemia Associated with Down Syndrome

Selinexor Prolongs Survival in Patient-Derived Xenograft Models of Down Syndrome Myeloid Leukemia

The menin-MLL1 interaction is a molecular dependency in NUP98 -rearranged AML

T Cell Engaging Bispecific Antibodies Produce Durable Response in Mesothelin-Positive Patient-Derived Xenograft Models of Pediatric AML

Hydrogel-Based 3D Culture Model for Down Syndrome Associated Transient Myeloproliferative Disorder Using Customized Induced Pluripotent Stem Cells

Introduction of STAG2 Mutation in an iPSC Model of Transient Abnormal Myelopoiesis Mimics Down Syndrome Myeloid Leukemia

Evaluating the Efficacy of PRMT5 Inhibitor C220 in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia

Bcl2 Inhibitor and DNA Hypomethylating Agent Prolong Survival in Patient-Derived Xenograft Model of Down Syndrome Myeloid Leukemia By Synergistic Downregulation of Cytokine Signaling

Epigenetic Drug Combination Alters Methylation Patterns in Patient-Derived Xenograft Models of KMT2A -Rearranged Pediatric AML Treated In Vivo

Imetelstat Significantly Reduces Leukemia Stem Cells in Patient-Derived Xenograft Models of Pediatric AML

Mesothelin Expression Is Associated with Extramedullary Disease and Promotes In Vivo Leukemic Growth in Acute Myeloid Leukemia

Mesothelin Targeting Bites for Pediatric AML: In Vivo Efficacy and Specificity

A Hydrogel Based 3D Culture System for Hematopoietic Differentiation of Induced Pluripotent Stem Cells

Modeling Transient Myeloproliferative Disorder Using Induced Pluripotent Stem Cells and CRISPR/Cas9 Technology

Generation, Characterization and Pre-Clinical Drug Evaluation of Patient-Derived Xenograft Models of Pediatric Down Syndrome AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only